This page collects WhisperX intelligence signals tagged #Autoimmune Hepatitis. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
A four-month regulatory delay from the U.S. Food and Drug Administration (FDA) forced a small biotech company to close its doors, illustrating the precarious path for firms navigating the drug approval process. Kezar Life Sciences had reached a breakthrough agreement with the FDA in February on a clinical trial plan fo...
A critical regulatory delay has forced a small biotech company to close its doors. Kezar Life Sciences, which was developing a treatment for the rare liver disease autoimmune hepatitis, secured a breakthrough agreement with the U.S. Food and Drug Administration in February on a plan for a pivotal clinical trial. Howeve...